Fintel reports that on September 11, 2023, Oppenheimer maintained coverage of Alpine Immune Sciences (NASDAQ:ALPN) with a Outperform recommendation.
Analyst Price Forecast Suggests 31.77% Upside
As of August 31, 2023, the average one-year price target for Alpine Immune Sciences is 16.93. The forecasts range from a low of 14.14 to a high of $19.95. The average price target represents an increase of 31.77% from its latest reported closing price of 12.85.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Alpine Immune Sciences is 48MM, an increase of 65.59%. The projected annual non-GAAP EPS is -1.42.
What is the Fund Sentiment?
There are 184 funds or institutions reporting positions in Alpine Immune Sciences. This is an increase of 20 owner(s) or 12.20% in the last quarter. Average portfolio weight of all funds dedicated to ALPN is 0.27%, a decrease of 7.35%. Total shares owned by institutions increased in the last three months by 6.68% to 37,344K shares. 
The put/call ratio of ALPN is 0.08, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 4,691K shares representing 9.53% ownership of the company. In it's prior filing, the firm reported owning 4,688K shares, representing an increase of 0.07%. The firm increased its portfolio allocation in ALPN by 11.13% over the last quarter.
Orbimed Advisors holds 4,082K shares representing 8.30% ownership of the company. No change in the last quarter.
Great Point Partners holds 3,364K shares representing 6.84% ownership of the company. In it's prior filing, the firm reported owning 3,741K shares, representing a decrease of 11.21%. The firm increased its portfolio allocation in ALPN by 19.38% over the last quarter.
Frazier Life Sciences Management holds 2,986K shares representing 6.07% ownership of the company. No change in the last quarter.
Lynx1 Capital Management holds 2,670K shares representing 5.43% ownership of the company. In it's prior filing, the firm reported owning 3,136K shares, representing a decrease of 17.44%. The firm decreased its portfolio allocation in ALPN by 10.89% over the last quarter.
Alpine Immune Sciences Background Information
(This description is provided by the company.)
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.
Additional reading:
- Alpine Immune Sciences Reports Second Quarter 2023 Financial Results --The Company will present preliminary data from RUBY-3 glomerulonephritis clinical study at the American Society of Nephrology Meeting in November 2023--
- AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALPINE IMMUNE SCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware)
- Alpine Immune Sciences Reports First Quarter 2023 Financial Results
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
